UCI-Founded Company Gets Acquired by Lineage

Carlsbad-based Lineage Cell Therapeutics Inc. has acquired NeuroAirmid Therapeutics Inc., and its clinical-stage program for treating Huntington’s disease. NeuroAirmid Therapeutics was founded on research led by UCI professor Leslie Thompson. The acquisition gives Lineage worldwide rights to the company’s HUNT1, a stem cell-derived neural cell therapy currently being evaluated in a Phase 1b/2a clinical trial at UCI Health. Shareholders in NeuroAirmid received $4.7 million in cash and Lineage shares at closing and are eligible for an additional $5 million payment next year, along with up to $48 million in development and regulatory milestones.

This excerpt comes from the named source. Read the original for the full reporting.